Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 15, 2026, 09:29Michele Brenner: A Personal Tragedy That Highlights the Urgency of DVT Awareness
-
Oct 15, 2026, 07:39Sian James: Welsh Blood Service Research Showcases Innovation and International Collaboration in Transfusion Medicine
-
Oct 15, 2026, 07:16Ruhi Mehra: Advancing Modern Transfusion Medicine Through Collaboration and Continuing Medical Education
-
Oct 15, 2026, 07:08Muhammet Özbilen: Iron Deficiency Beyond Hemoglobin Exploring Mitochondrial and Metabolic Dysfunction
-
Oct 15, 2026, 06:44Ahlem Slama: World Thrombosis Day 2026 Lighting Up Heritage to Raise Awareness
-
Oct 15, 2026, 06:32Joshua Muia: World Thrombosis Day 2026 Highlights Research on Tissue Factor and Blood Coagulation
-
Oct 14, 2026, 20:36How Does Inflammation Reshape Red Blood Cell Production? – ASH
-
Oct 14, 2026, 20:30Marilena Vrana: Putting Faces to the Chain – Donors and Patients Connect in Milan for IPAW 2026
-
Oct 14, 2026, 20:25Asim Alam: Hillsborough County and Partners Demonstrate Drone-Based Emergency Blood Delivery